Homocysteine and pregnancy

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 3, 2003, Pages 459-469

  Hague, William Martin ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Abruption; Folate; Homocysteine; MTHFR; Neural tube defect; Pre eclampsia; Recurrent pregnancy loss

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; COLESTYRAMINE; CONTRACEPTIVE AGENT; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; ESTROGEN; FOLIC ACID; FOLIC ACID ANTAGONIST; HOMOCYSTEINE; LEVODOPA; METHIONINE SYNTHASE; METHOTREXATE; NICOTINIC ACID; NITROUS OXIDE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; BIOCHEMISTRY; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIET; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASE; LIFESTYLE; METHYLATION; MOTHER; NEURAL TUBE DEFECT; NONHUMAN; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DISORDER; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SOLUTIO PLACENTAE; SULFATION; THROMBOEMBOLISM; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

EID: 0038718744     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00009-9     Document Type: Review

References (51)

1. Carson N, Cusworth D, Dent C et al. Homocystinuria: A new inborn error of metabolism associated with mental deficiency. Archives of Disease in Childhood 1963; 38: 425-436.
2. Mudd S, Finkelstein J, Irreverre F & Laster L. Homocystinuria: An enzymatic defect. Science 1964; 143: 1443-1445.
3. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. American Journal of Pathology 1969; 56: 111-128.
4. Wilcken DE & Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. Journal of Clinical Investigation 1976; 57: 1079-1082.
5. Boushey CJ, Beresford SA, Omenn GS & Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Journal of the American Medical Association 1995; 274: 1049-1057. (see comments).
6. Brattstrom L & Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? American Journal of Clinical Nutrition 2000; 72: 315-323.
7. Dudman N. An alternative view of homocysteine. Lancet 1999; 354: 2072-2074.
8. Collaboration HLT. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. British Medical Journal 1998; 316: 894-898.
9. Andersson A. Homocysteine export from erythrocytes and its implication for plasma sampling. Clinical Chemistry 1992; 38: 1311-1315.
10. Duarte NL, Wang XL & Wilcken DE. Effects of anticoagulant and time of plasma separation on measurement of homocysteine. Clinical Chemistry 2002; 48: 665-668.
11. Candito M, Bedoucha P, Gibelin P et al. Fasting, postprandial, and post-methionine-load homocysteinaemia and methylenetetrahydrofolate reductase polymorphism in vascular disease. Journal of Inherited Metabolic Disease 1999; 22: 588-592.
12. Silberberg J, Crooks R, Fryer J et al. Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading. Atherosclerosis 1997; 133: 105-110.
13. Dekker G, De Vries J & Doelitzsch P. Underlying disorders associated with severe early-onset pre-eclampsia. American Journal of Obstetrics and Gynecology 1995; 173: 1042-1048.
14. Silberberg J & Dudman N. Methionine loading. In Carmel R & Jacobsen D (eds) Homocysteine in Health and Disease pp 212-219: Cambridge: Cambridge University Press, 2001.
15. Van Der Put NM, Eskes TK & Blom HJ. Is the common 677C → T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. Quarterly Journal of Medicine 1997; 90: 111-115.
16. Hira B, Pegoraro RJ, Rom L et al. Polymorphisms in various coagulation genes in black South African women with placental abruption. British Journal of Obstetrics and Gynaecology 2002; 109: 574-575.
17. Van Der Put NMJ, Gabreëls F, Stevens EMB et al. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? American Journal of Human Genetics 1998; 62: 1044-1051.
18. Weisberg IS, Jacques PF, Selhub J et al. The 1298A → C polymorphism in methylenetetrahydrofolate reductase (MTHFR): In vitro expression and association with homocysteine. Atherosclerosis 2001; 156: 409-415.
19. Rozen R. Genetic modulation of homocysteinemia. Seminars in Thrombosis and Hemostasis 2000; 26: 255-261.
20. Andersson A. Decreased serum homocysteine in pregnancy. European Journal of Clinical Chemistry and Clinical Biochemistry 1992; 30: 377-379.
21. Hague B, Whiting M & Tallis G. South Australian experience with hyperhomocysteinaemia as a risk factor in obstetrics. Time for a trial? The Netherlands Journal of Medicine 1997; 52(supplement): S24.
22. Steegers-Theunissen R, Boers G, Trijbels F & Eskes T. Neural tube defects and derangement of homocysteine metabolism. New England Journal of Medicine 1991; 324: 199-200.
23. Malinow MR, Rajkovic A, Duell PB et al. The relationship between maternal and neonatal umbilical cord plasma homocyst(e)ine suggests a potential role for maternal homocyst(e)ine in fetal metabolism. American Journal of Obstetrics and Gynecology 1998; 178: 228-233.
24. Anonymous, Prevention of neural tube defects: Results of the medical research council vitamin study. MRC vitamin study research group. Lancet 1991; 338: 131-137. (see comments).
25. Czeizel AE & Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. New England Journal of Medicine 1992; 327: 1832-1835. (see comments).
26. Lumley J, Watson L, Watson M & Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects (Cochrane Review). The Cochrane Library Issue 3, Oxford: Update Software, 2002.
27. Mills JL, McPartlin JM, Kirke PN et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345: 149-151. (see comments).
28. Moephuli SR, Klein NW, Baldwin MT & Krider HM. Effects of methionine on the cytoplasmic distribution of actin and tubulin during neural tube closure in rat embryos. Proceedings of the National Academy of Sciences of the USA 1997; 94: 543-548.
29. Rosenquist TH, Ratashak SA & Selhub J. Homocysteine induces congenital defects of the heart and neural tube: Effect of folic acid. Proceedings of the National Academy of Sciences of the USA 1996; 93: 15227-15232.
30. Rosenquist TH, Andaloro V, Monaghan D & Selhub J. Homocysteine and congenital defects: A role for the NMDA receptor. Netherlands Journal of Medicine 1998; 52(supplement): S17.
31. Van Der Put NM, Steegers-Theunissen RP, Frosst P et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1071. (see comments).
32. Rajkovic A, Mahomed K, Malinow MR et al. Plasma homocyst(e)ine concentrations in eclamptic and preeclamptic African women postpartum. Obstetrics and Gynecology 1999; 94: 355-360.
33. Powers RW, Evans RW & Majors AK. Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation. American Journal of Obstetrics and Gynecology 1998; 179: 1605-1611.
34. Powers RW, Evans RW, Ness RB et al. Homocysteine and cellular fibronectin are increased in preeclampsia, not transient hypertension of pregnancy. Hypertension in Pregnancy 2001; 20: 69-77.
35. Vollset SE, Refsum H & Irgens LM. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: The Hordaland homocysteine study. American Journal of Clinical Nutrition 2000; 71: 962-968. (see comments).
36. Plantinga J, Hague W, Fitridge R et al. Obstetric history and thrombophilia in women with early onset atherosclerosis. Australasian Society for the Study of Hypertension in Pregnancy Annual Scientific Meeting, Akaroa, New Zealand; 2002.
37. Sibai BM, Mercer B & Sarinoglu C. Severe preeclampsia in the second trimester: Recurrence risk and long-term prognosis. American Journal of Obstetrics and Gynecology 1991; 165: 1408-1412.
38. Leeda M, Riyazi N, De Vries JI et al. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal growth restriction. American Journal of Obstetrics and Gynecology 1998; 179: 135-139.
39. Currie L, Peek M, McNiven M et al. Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? BJOG: An International Journal of Obstetrics and Gynaecology 2002; 109: 191-196.
40. Ray JG & Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: A systematic review. Placenta 1999; 20: 519-529.
41. Khong T & Hague W. The placenta in hyperhomocysteinaemia. British Journal of Obstetrics and Gynaecology 1999; 106: 273-278.
42. Goddijn-Wessel T, Wouters M, Vandermolen E et al. Hyperhomocysteinaemia - A risk factor for placental abruption or infarction. European Journal of Obstetrics, Gynecology and Reproductive Biology 1996; 66: 23-29.
43. Owen EP, Human L, Carolissen AA et al. Hyperhomocysteinemia - A risk factor for abruptio placentae. Journal of Inherited Metabolic Disease 1997; 20: 359-362.
44. Van Der Molen E, Verbruggen B, Novakova L et al. Hyperhomocysteinaemia and other thrombotic risk factors in women with placental vasculopathy. British Journal of Obstetrics and Gynaecology 2000; 107: 785-791.
45. Van Der Molen EF, Arends GE, Nelen WL et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene as a new risk factor for placental vasculopathy. American Journal of Obstetrics and Gynecology 2000; 182: 1258-1263.
46. Eskes TK. Clotting disorders and placental abruption: Homocysteine - A new risk factor. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2001; 95: 206-212.
47. Wouters M, Boers G, Blom H et al. Hyperhomocysteinaemia: A risk factor in women with unexplained recurrent pregnancy loss. Fertility and Sterility 1993; 60: 820-825.
48. Coumans AB, Huijgens PC, Jakobs C et al. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Human Reproduction 1999; 14: 211-214.
49. Nelen WL, Blom HJ & Steegers EA. Hyperhomocysteinemia and recurrent early pregnancy loss: A meta-analysis. Fertility and Sterility 2000; 74: 1196-1199.
50. Isotalo P, Wells G & Donnelly J. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: An examination of C677T and A1298C mutations. American Journal of Human Genetics 2000; 67: 986-990.
51. Zetterberg H, Regland B & Palmer M. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. European Journal of Human Genetics 2002; 10: 113-118.